04/25/2025 07:00
Erbe introduces VIO® 3n & VIO® seal: Tailored electrosurgical generators for high-performance workflows

With the introduction of the VIO® 3n, Erbe Elektromedizin GmbH expands its established VIO® 3 family with a new generation of electrosurgical generators, specifically tailored to different medical specialties and procedural requirements. The portfolio is further enhanced by the VIO® seal, the first VIO® generator fully dedicated to bipolar applications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425843193/en/VIO 3n Fire Five c...

04/29/2025 07:29
SINOVAC Board Issues Letter to Shareholders to Set the Record Straight on the Hostile Actions and False Claims by Vivo Capital

Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that its board of directors (the “Board”) issued a public letter to shareholders in response to hostile actions and false claims by Vivo Capital and certain other parties (the “Vivo group”) against the legitimate and lawful actions of the Board. Dear Shareholders, We are writing to set the record straight in response to the Vivo group’s recent press relea...

04/29/2025 07:29
Suzano 2024 Annual Report on Form 20-F

Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2024 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: [email protected]. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: P...

05/15/2025 18:30
Incyte Announces FDA Approval of Zynyz® (retifanlimab-dlwr) Making it the First and Only Approved First-Line Treatment for Advanced Anal Cancer Patients in the United States

Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Zynyz® (retifanlimab-dlwr), a humanized monoclonal antibody targeting programmed death receptor-1 (PD-1), in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC). In addition, the FDA granted approval for Zynyz as a single agent for th...

05/27/2025 01:00
Acceleronix to Showcase Innovative IoT Solutions at CommunicAsia 2025 in Singapore

Acceleronix, a global leader in IoT solutions and services, is excited to announce its participation in CommunicAsia, taking place on May 27th in Singapore, presenting its comprehensive offerings, including the Acceleronix Core PaaS/SaaS, Connectivity Management Platform (CMP), and connectivity solutions. These services are designed to simplify the design and go-to-market processes for OEMs and ODMs across the Asia-Pacific region and beyond. “We’re excited to be at CommunicAsia in Singapore, ...

05/27/2025 01:00
Quectel Highlights Advanced IoT Modules, Antenna, GNSS, and 5G Solutions at CommunicAsia Singapore

Quectel Wireless Solutions, a global IoT solutions provider, is pleased to announce its participation in the CommunicAsia event held in Singapore, where it will showcase its comprehensive portfolio of IoT products and services designed to help customers build a smarter, more connected world. “We’re excited to welcome attendees back to our stand at CommunicAsia this year, where we’ll be showcasing Quectel’s latest innovations in IoT,” said Yasu Okada, Senior Sales Director APAC at Quectel Wire...

04/25/2025 07:28
Ant Group Unveils New Recruitment Initiative for Top AI Talents, Ramping Up AI Innovation Efforts

Ant Group today unveiled Plan A, a new recruitment initiative to attract top artificial intelligence researchers, reinforcing its commitment to accelerating AI research and development under the “AI First” corporate strategy. Operating within the framework of Ant Star—Ant Group’s year-round campus recruitment program—Plan A specifically targets AI talents who are ambitious, adaptable, altruistic, and analytical. Outstanding graduates from universities worldwide with STEM majors are encouraged ...

04/29/2025 07:30
CSG and NetLync Drive MNO and MVNO eSIM Transformation

With eSIM set to become the standard for all new phones this year, mobile network operators (MNOs) and mobile virtual network operators (MVNOs) face mounting pressure to modernize their entitlement infrastructure. To address this market need, CSG® (NASDAQ: CSGS) today announced a new partnership with leading entitlement server provider NetLync and launched CSG Entitlements-as-a-Service, powered by NetLync. This new SaaS platform gives operators the speed and agility they need to power seamless ...

05/27/2025 01:30
JT Group Launches Ploom AURA and EVO Heated Tobacco Sticks in Japan

Japan Tobacco Inc. (JT)(TSE:2914) launches Ploom AURA, its next generation heated tobacco device, on May 27, 2025, in Japan, primarily in its Ploom stores and CLUB JT online shop. In parallel, JT Group will roll out EVO, its exclusive and premium heated tobacco sticks (HTS), to complement Ploom AURA and provide adult consumers with the latest and most technologically advanced propositions in the heated tobacco segment. A nationwide launch of Ploom AURA and EVO will start on July 1 in convenienc...

05/27/2025 03:50
Revolutionizing Healthcare: Ubitus and MacKay Memorial Hospital Present AI Robot Collaboration at GTC Taiwan

Ubitus, a global leader in cloud streaming and AI solutions, announced its collaboration with MacKay Memorial Hospital to unveil AI-powered multi-modal medical robots at NVIDIA GTC Taiwan 2025. The presentation, “AI-Enabled Healthcare: Multi-Modal Robot Collaboration Inspired by MacKay’s Case Study,” will highlight how NVIDIA technologies— NVIDIA Blackwell GPUs, NVIDIA Omniverse, NVIDIA Isaac GR00T, NVIDIA ACE, and NVIDIA Jetson AGX Orin—are transforming smart healthcare through automation, imp...